Communiqués SynAct Pharma AB

Actions

SYNACT

SE0008241491

Produits pharmaceutiques

Temps Différé Nasdaq Stockholm Autres places de cotation 11:38:25 08/07/2026			Varia. 5j.	Varia. 1 janv.
18,40 ^SEK	-4,66%		-12,21%	-18,23%

29/06	Synact Pharma : regain d'intérêt des partenaires pour le resomelagon après l'étude Advance	FW
29/06	SynAct Pharma fait le point après sa participation à la convention internationale BIO 2026 à San Diego	CI

Communiqués

02/07	SynAct Pharma : Company presentation	PU
02/07	SynAct Pharma : Bolagspresentation	PU
29/06	BIO International USA confirms growing interest in resomelagon and SynAct Pharma following the positive effects of the ADVANCE study	AQ
16/06	SynAct Pharma: Updated Base Case after ADVANCE	AQ
15/06	SynAct Pharma (Interview): ADVANCE Topline Data	AQ
15/06	SynAct Pharma: 40mg Best Dose in ADVANCE	AQ
15/06	SynAct Pharma Board of Directors and Management Enter Lock-up Agreements	AQ
15/06	SynAct Pharma : Phase 2b ADVANCE study demonstrates positive effects of resomelagon in Rheumatoid Arthritis - supports phase 3 design, regulatory interactions, and partnering	PU
15/06	Phase 2b ADVANCE study demonstrates positive effects of resomelagon in Rheumatoid Arthritis – supports phase 3 design, regulatory interactions, and partnering	AQ
12/06	SynAct obtains key US patent for resomelagon securing exclusivity until 2044	AQ
11/06	Report from the 2026 Annual General Meeting of SynAct Pharma AB (publ)	AQ
27/05	SynAct Pharma publishes Q1 2026 interim results	AQ
26/05	Synact Pharma large shareholder trading update	AQ
19/05	SynAct Pharma to present at the BioStock Global Forum 2026 on May 21	AQ
07/05	Notice of annual general meeting in SynAct Pharma AB	AQ
06/05	SynAct Pharma completes dosing in phase IIb ADVANCE study ahead of June readout	AQ
06/05	SynAct Pharma completes dosing for last patient in Phase 2b ADVANCE study	AQ
05/05	SynAct Pharma to participate at the LSX Nordic Congress on May 19-20, 2026 in Copenhagen	AQ
27/04	What good data looks like: SynAct Pharma ahead of its ADVANCE readout	AQ
23/04	SynAct Pharma : Nomination Committee ahead of the 2026 Annual General Meeting	PU
23/04	SynAct Pharma’s Nomination Committee ahead of the 2026 Annual General Meeting	AQ
16/04	SynAct Pharma : Company presentation	PU
16/04	SynAct Pharma : Bolagspresentation	PU
15/04	SynAct Pharma publishes Annual Report 2025	AQ
26/03	SynAct Pharma doses first patients in the Phase 2 RESOVIR-2 study with resomelagon	AQ